An FDA inspection of the Zhejiang Huahai Pharmaceutical plant a year ahead of its global recall of tainted heart drug valsartan found a plant with little regard for quality control and which blamed out-of-specification test results on “ghost peaks,” lab e
Healthcare professionals and patients have been alerted by the U.S. Food and Drug Administration (FDA) of a voluntary recall of drugs containing the active ingredient valsartan. This active ingredient is used in drugs to treat high blood pressure and hear
The European Medicines Agency is reviewing medicines containing valsartan supplied by a facility in China after a potentially cancer-causing impurity was detected.
The European Medicines Agency is reviewing medicines containing valsartan supplied by a facility in China after a potentially cancer-causing impurity was detected.